

Nephrotic Syndrome (Genitourinary Disorders) - Drugs in Development, 2021

<https://marketpublishers.com/r/NC550AC5BCE1EN.html>

Date: September 2021

Pages: 64

Price: US\$ 2,000.00 (Single User License)

ID: NC550AC5BCE1EN

Abstracts

Nephrotic Syndrome (Genitourinary Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Drugs In Development, 2021, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape. Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and

discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.

Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And

Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Nephrotic Syndrome - Overview
- Nephrotic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Nephrotic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Nephrotic Syndrome - Companies Involved in Therapeutics Development
- Adare Pharma Solutions
- APIE Therapeutics Inc
- Asahi Kasei Pharma Corp
- Bristol-Myers Squibb Co
- ChemoCentryx Inc
- Energenisis Biomedical Co Ltd
- Evergreen Therapeutics Inc
- Ninevah Therapeutics SL
- Pharmapraxis
- SynAct Pharma AB
- Nephrotic Syndrome - Drug Profiles
- abatacept - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AP-1189 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- APT-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EG-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-710 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilacirnon sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mizoribine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTX-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prednisone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nephrotic Syndrome - Dormant Projects

Nephrotic Syndrome - Product Development Milestones

Featured News & Press Releases

Aug 25, 2021: SynAct strengthens IP portfolio - Grant of key European patent covering AP1189

Jun 29, 2020: SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

Jun 02, 2020: SynAct Pharma's clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional

therapy in hospitalized patients with COVID-19

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nephrotic Syndrome, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Nephrotic Syndrome - Pipeline by Adare Pharma Solutions, 2021

Nephrotic Syndrome - Pipeline by APIE Therapeutics Inc, 2021

Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, 2021

Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Co, 2021

Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, 2021

Nephrotic Syndrome - Pipeline by Energenisis Biomedical Co Ltd, 2021

Nephrotic Syndrome - Pipeline by Evergreen Therapeutics Inc, 2021

Nephrotic Syndrome - Pipeline by Ninevah Therapeutics SL, 2021

Nephrotic Syndrome - Pipeline by Pharmapraxis, 2021

Nephrotic Syndrome - Pipeline by SynAct Pharma AB, 2021

Nephrotic Syndrome - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nephrotic Syndrome, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Nephrotic Syndrome (Genitourinary Disorders) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/NC550AC5BCE1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NC550AC5BCE1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970